ROPINIROLE KRKA LP 8 mg, extended-release tablet 28 tablets
Active ingredients: Ropinirole hydrochloride, Ropinirol
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ROPINIROLE KRKA LP 8 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) polyamide aluminium PVC-Aluminium de 28 comprimé(s)
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Jun 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65999613CIP74164052CIP133400941640520Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE ROPINIROLEcomprimé | — | SA |
| ROPINIROLE BASEcomprimé | 8 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.